Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05317481 · ClinicalTrials.gov registry record · NA
Reducing Suicide Risk in Adolescents and Young Adults Via a Psychobehavioral Intervention to Regularize Daily Rhythms
A NA study of Major Depressive Disorder and Bipolar Disorder, sponsored by Yale University.
- Completed
- Registry status
- NA
- Development phase
- 65
- Enrollment target
- 2
- Study locations
NCT05317481: Completed NA study of Major Depressive Disorder and Bipolar Disorder, sponsored by Yale University.
NCT05317481 is a NA study of Major Depressive Disorder and Bipolar Disorder that has completed, run by Yale University. The registered enrollment target is 65 participants, below the 377-participant average among 282 other Major Depressive Disorder trials with a reported enrollment target (83% lower). The trial reports 2 study locations across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05317481, a NA study of Major Depressive Disorder and Bipolar Disorder, has completed, sponsored by Yale University.
- COMPLETED
- Registry status
- NA
- Development phase
- 65 participants
- Enrollment target
- 2
- Study locations
Study Summary
The purpose of this study is to advance a non-pharmacologic suicide preventive intervention with wide dissemination potential as an innovative high-yield solution to reduce suicide rates. The investigators aim to achieve this with this study of Brain Emotion Circuitry Self-Monitoring and Regulation Therapy for Daily Rhythms (BE-SMART-DR), that provides self-directed strategies to regularize sleep and other DRs to reduce short-term suicide risk that can be used lifelong to potentially also reduce long-term suicide risk.
Primary Outcome
CHRT-SR is a validated, self-reported measure with a propensity subscore (9 items) identifying risk factors. Each item is scored on a five-point Likert scale with responses ranging from 0 ("Strongly disagree") to 4 ("Strongly agree"), thereby creating a total propensity score ranging from 0-36,with higher scores showing higher levels of suicidal propensity.
Conditions Studied
Interventions
- BEHAVIORAL BE-SMART-DR
- BEHAVIORAL psychoeducational control comparator condition (CC)
Study Locations (2)
Connecticut
- Magnetic Resonance Research Center - New Haven
- Mood Disorders Research Program - New Haven
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 65 participants |
| Start Date | 2022-04-01 |
| Est. Completion | 2025-03-31 |
| Phase | NA |
What the finished NCT05317481 record still lists
NCT05317481 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 65 participants, a relatively small participant target, below the 377-participant average among 282 other Major Depressive Disorder trials with a reported enrollment target (83% lower).
The record links to 5 conditions, with Major Depressive Disorder appearing as the primary indexed condition, and to 2 interventions - of which BE-SMART-DR is the first listed.
NCT05317481 reports a single indexed study location in Connecticut.
Frequently Asked Questions
What is clinical trial NCT05317481 about?
NCT05317481 is a clinical study titled "Reducing Suicide Risk in Adolescents and Young Adults Via a Psychobehavioral Intervention to Regularize Daily Rhythms". The purpose of this study is to advance a non-pharmacologic suicide preventive intervention with wide dissemination potential as an innovative high-yield solution to reduce suicide rates. The investigators aim to achieve this with this study of Brain Emotion Circuitry Self-Monitoring and Regulation ...
What is the current status of trial NCT05317481?
This trial is currently completed. It is a NA study. The enrollment target is 65 participants. The study started on 2022-04-01. Estimated completion is 2025-03-31.
What conditions does trial NCT05317481 study?
This clinical trial studies the following conditions: Major Depressive Disorder, Bipolar Disorder, Suicide, Suicidal Ideation, Mood Disorders.
What interventions are being tested in trial NCT05317481?
The interventions under investigation include: BE-SMART-DR (BEHAVIORAL), psychoeducational control comparator condition (CC) (BEHAVIORAL).
Who is sponsoring clinical trial NCT05317481?
This trial is sponsored by Yale University, which has 1,492 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05317481 being conducted?
This trial has 2 study locations across Connecticut. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Major Depressive Disorder
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05317481's enrollment target sits among peer trials
65 163rd of 282 higher than 119 of 282 other Major Depressive Disorder trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Major Depressive Disorder trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Taking Action for College Students
RECRUITING · NA
-
Targeting Large-scale Networks in Depression With Real-time Functional Magnetic Resonance Imaging (fMRI) Neurofeedback
RECRUITING · NA
-
Neural Correlates of Stress and Perceived Control in Adolescent Depression
RECRUITING · NA
-
Positive Processes and Transition to Health (PATH)
RECRUITING · NA
-
Getting Out of the House: Using Behavioral Activation to Increase Community Participation
RECRUITING · NA
-
Amygdala Neurofeedback for Depression - Large Scale Clinical Trial
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03366116 · 65 participants · Phase 1
5-aza-4'-Thio-2'-Deoxycytidine (Aza-TdC) in People With Advanced Solid Tumors
- NCT03603730 · 65 participants · NA
Vagal Nerve Stimulation for Functional Dyspepsia and Gastroparesis
- NCT03796559 · 65 participants · NA
Magseed Enabled Long-Term Localization of Axillary Lymph Nodes
- NCT03993106 · 65 participants · Phase 2
A Study of sEphB4-HSA in Kaposi Sarcoma
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI